Who Owned Georgia English.pdf

Another pharmaceutical professional, speaking to TI Georgiaon condition of anonymity, said that by selling these shareddrugs at prices 10% below the retail value, the companies areable to put smaller competitors out of business. 233 But GochaGogilashvili, General Director of PSP, stated that a fixed marginis normal market practice and is how a company makes a profiton its distribution of medicines they don’t sell in their ownpharmacies. 234 What isn’t normal, though, is that the largestimporter/distributor is also the largest retailer. There’s nothingtechnically wrong with being a distributor/retailer, it’s just thatin this case, the large companies use their dominant position as adistributor to strengthen their position on the retail level.In 2009, the government stepped in to adopt new amendmentsto increase market competition. Importers now have thepossibility to select the cheapest version of a certain medicine ina particular country and to look for new medicines that had notbeen allowed in Georgia or were very difficult to distribute onthe Georgian market. 235 Companies have more opportunities toimport a medical product through different channels. While thechanges were welcomed, they have little effect on the currentsituation, as the main players still dominate the market. 236Because they are the largest distributors on the market,Aversi, PSP and GPC benefit from the small, fragmented retailoutlet market that cannot afford to import their own medicines.Even the investment guide for the pharmaceutical market states233 Interview with respondent who refers to stay anonymous on 3 October. 2011Report on Pharmaceutical Market in Georgia. Transparency InternationalGeorgia http://transparency.ge/sites/default/files/post_attachments/The%20Pharmaceutical%20Market%20in%20Georgia_June%202012l_0.pdf Accessed05/12/2012234 Interview Gocha Gogilashvili, General Director PSP. Report onPharmaceutical Market in Georgia. Page 18Transparency InternationalGeorgia http://transparency.ge/sites/default/files/post_attachments/The%20Pharmaceutical%20Market%20in%20Georgia_June%202012l_0.pdf Accessed05/12/2012235 Ibid p. 15236 Ibid p. 2957